已阅读5页,还剩41页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
ManagementofHeartFailure:Past,PresentandFuture,LexinWang,M.D.,Ph.D.,FCSANZProfessorofClinicalPharmacologyHead,CardiovascularResearch,Objectives,HistoryandpathogenesisEpidemiologyandriskfactorsCurrentmanagementFuturedirections,Katz,A.M.CircHeartFail2008;1:63-71,WilliamHarvey,1628,Changingviewsofheartfailure1.Aclinicalsyndrome2.Acirculatorydisorder3.Alteredarchitectureoftheheart4.Abnormalhemodynamics5.Disorderedfluidbalance6.Biochemicalabnormalities7.Maladaptivehypertrophy8.Genomics9.Epigenetics(实验胚胎学),Katz,A.M.CircHeartFail2008;1:63-71,Changingmanagementofheartfailureoverthepast40years,CHF-Prevalence,Approximately5.5millionAmericanshaveCHF(2.2%ofthepopulation)550,000newcasesannuallyAccountsfor12millionclinicvisitsperyearEstimatedhealthcarecostsin2004isUS$28.8billion,CHFprevalence-Australia,2%ofadultpopulationApproximately241,000patients30,000newcaseseachyear42,000hospitalisationsin2004-2005Accountsfor0.8%ofallhospitalisationsinthecountry,Age-relatedprevalenceofCHF,AmericanNationalHFproject34,587hospitalizedpatients,Age(median,yrs)73Gender(female,%)59%History(%)hypertension61%coronaryarterydisease56%diabetes38%COPD33%atrialfibrillation30%HavranekEPetal.AmHeartJ2002;143:412-417,ClassificationofCHF,SystolicCHFWeakenedabilityoftheventriclestocontractHeartfailurewithpreservedsystolicfunctionImpaireddiastolicfillingoftheleftventricle,resultinginhighfillingpressure,withorwithoutsystolicdysfunctionAccounts40%ofallCHF,ManagementofCHF,LifestylechangesPharmacologicalSurgicalDevicesCABG,PCICardiactransplantation,Drugtherapy,STEP1Confirmleftventricularsystolicdysfunction(LVSD)byEchocardiographyRadionuclideventriculography,orRadiologicalleftventricularangiography,Drugtherapy,STEP2Initiatefirst-linetherapyinallpatientswithheartfailureduetoLVSDwithadiureticandanACEinhibitorforNYHAclassI-IV,andabeta-blockerforNYHAclassII-III,unlessthesearecontra-indicated,Drugtherapy,STEP3Initiatesecond-linetherapyinpatientswithpersistentsignsandsymptomsofheartfailure(NYHAclassIII/IV)withspironolactoneanddigoxinInitiatespironolactonefirstfollowedbydigoxin,bothatalowdoseandthenup-titrate,checktolerabilityandbloodchemistry.,Co-operativeNorthScandinavianEnalaprilSurvivalStudyICONSENSUSINEnglJMed1987;316:14291435,StudiesofLeftVentricularDysfunctionSOLVD(TreatmentStudy)SOLVDInvestigatorsNEnglJMed1991;325:293302,NEnglJMed2003;349:18931906,VALIANT:Results,NEnglJMed2003;349:18931906,VALIANT:Adverseevents,UnitedStatesCarvedilolProgram(USCP)PackerMetal.NEnglJMed1996;334:13491355,CardiacInsufficiencyBisoprololStudyII(CIBISII)CIBISIIInvestigators,Lancet1999;359:913,MetoprololCR/XLRandomizedInterventionTrialinCongestiveHeartFailure(MERIT-HF)HjalmarsonAetal.Lancet1999;353:20012007,Remme,W.J.etal.JAmCollCardiol2007;49:963-971,CombinedEndPointofanyMI,UnstableAngina,andStroke,Remme,W.J.etal.JAmCollCardiol2007;49:963-971,DeathAfteraNonfatalMyocardialInfarctionorNonfatalStroke,CCBs:NHFrecommendations,AmlodipineandfelodipinecanbeusedtotreatcomorbiditiessuchashypertensionandCHDinpatientswithsystolicCHFTheyhavebeenshowntoneitherincreasenordecreasemortality.Non-dihydropyridinecalcium-channelblockerssuchasverapamilanddiltiazemarecontraindicatedinpatientswithsystolicheartfailure,Electromechanicaldysfunction,Definedasanyabnormalityinthegenerationortransmissionofelectricalimpulsesthatresultsinclinicallysignificantalterationinthemechanicalfunctionoftheheart,65-year-oldmale,LBBB,LVEF20%,Cardiacresynchronizationtherapy(biventricularpacing),inappropriatelyselectedpatients:improvessymptomsimprovesexerciseperformanceimprovesQOLimproveslong-termmorbidity7:212.,TABLE2.RiskofSuddenCardiacDeath,RiskofSuddenCardiacDeath,SaxonLAetal.Circulation.2006;114:2766-72.,IndicationsforCRTNYHAIII-IV,despiteoptimalmedicaltherapyDilatedheartfailurewithEF120msSinusrhythm,FuturedirectionsCell-BasedTherapiesEmbryonicstemcellsBonemarrowcells(containsstemcellsandprogenitorcells)Circulatingblood-derivedprogenitorcells(EPCs),Cell-BasedTherapiesSeveralsmalltrialsdemonstratedimprovementofLVfunctionChallengesCurrentstudiesaretoosmalltoassessclinicaloutcomesMethodofpreparationanddeliveryuncertainThebesttypeofcellstouseisstillunclear,GeneTherapyMajorchallengesDevelopmentofanidealvector(e.g.adenovirus)AmethodofdeliveryofthesevectorsIdentificationofappropriategenetargets,e.g.cardiacS100A1,acalciumbindinggene,andsarcoplasmicreticularCa2+gene,MechanicalassistanceCardiactransplantationwillalwaysbelimitedtheavailabilityofdonorheartsVentricularassistdevices(VADs)MainlyusedasbridgestotransplantationAsdestinationtherapy?REMATCHtrial:encouragingbutthedevicewastoolargewithmanycomplications,Ventricularassistdevices(VADs)CurrenteffortReducetheincidenceofcomplicationsandsizeofthedeviceIndicationsforVADsareexpectedtoexpandquicklyinthenextfiveyearstoprovidedestinationtherapy,ConclusionsThefieldofHFstudyisnowatahistoricjunctureThepandemicofHFisincreasingrapidlybecauseoftheagingpopulationandincreasednumberofsurvivalpatientsfollowingMIStudiesonpreventionandmanagementofHFisaccelerating,Conclusions(continued)Advancesingenetics,cellbiologyandmolecularpharmacologywillenhanceunderstandingofthecausesofHFCurrentlyusedACEI,beta-blockersandCRThaveclearbenefitstoclinicaloutcomesofHFDevelopmentinbioengineeringcouldhaveanenormousbeneficialimpactonbothincidenceandmanagement,Chronicheartfailure(CHF),Definitionacomplexclinicalsyndromewithtypicalclinicalsymptomsthatcanoccuratrestoroneffort,andischaracterisedbyobjectiveevidenceofanunderlyingstructuralabnormalityorcardiacdysfunctionthatimpairstheventricletofillwithorejectbloodThetermcongestiveheartfailureisnolongerused.,MADIT-II,MossAJ.NEnglJMed.2002;346:877-83.,Defibrillator,Conventional,P=0.007,1.0,0.9,0.8,0.7,0.6,0.0,ProbabilityofS
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 音乐社团个人期末总结(30篇)
- 甘肃省靖远一中2024届高考仿真卷语文试卷含解析
- 酒店人事部门工作总结范文(30篇)
- 财务工作管理总结范文(25篇)
- 2024广西靖西市区外招聘急需紧缺人才19人历年高频考题难、易错点模拟试题(共500题)附带答案详解
- 临床专科《妇产科学》复习题及答案
- 亲子活动手工diy主持词
- 农产品食品安全评价技术 课件 模块七 食品添加剂检测
- 形象塑造心得(14篇)
- 账款催收通知范文(21篇)
- 高中心理健康《拒绝精神内耗》主题班会课件
- 对我国偷逃增值税现象的分析毕业论文
- 公路造价工程量清单报价表
- 为什么是中国
- 中建装饰云筑网平台操作培训
- ADA糖尿病治疗指南
- 团体标准《橡胶制品工业大气污染防治可行技术指南(征求意见稿)》发布
- 西方国际关系理论智慧树知到答案章节测试2023年国际关系学院
- 格力电器的企业文化
- 2023年先进材料发展指数吴江指数 -赛迪
- GB/T 16129-1995居住区大气中甲醛卫生检验标准方法分光光度法
评论
0/150
提交评论